Active Biotech
0,379 SEK -5,25%1 investor følger denne virksomhed
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ACTI
Daglig lav / høj pris
0,37 / 0,41
SEK
Markedsværdi
137,13 mio. SEK
Aktieomsætning
143,79 t SEK
Volumen
378 t
Seneste videoer
Finanskalender
Delårsrapport
07.11.2024
Årsrapport
13.02.2025
Delårsrapport
08.05.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| MGA Holding AB | 28,1 % | 28,1 % |
| Sjuenda Holding | 7,4 % | 7,4 % |
| Handelsbanken Liv | 5,3 % | 5,3 % |
| Avanza Pension | 4,7 % | 4,7 % |
| Fjärde AP Fonden | 4,7 % | 4,7 % |
| Tredje AP-fonden | 3,7 % | 3,7 % |
| SEB-Stiftelsen, Skand Enskilda | 1,4 % | 1,4 % |
| SEB Life International Assurance | 1,0 % | 1,0 % |
| Nordnet Pensionsförsäkring | 0,9 % | 0,9 % |
| Stävie Förvaltning | 0,9 % | 0,9 % |
ViserAlle indholdstyper
Active Biotech Interim Report Q2 2024
Active Biotech provides update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools